YAP101 Passes First Safety Milestone in Clinical Trial

November 12, 2025

We're excited to announce that YAP101 has successfully passed its initial safety evaluation in the first-ever clinical trial of a gene therapy designed to regenerate human heart tissue!

Medley Therapeutics (formerly YAP Therapeutics) has completed dosing of the first cohort of patients in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine. After careful evaluation, the independent Safety Review Team reported favorable safety findings and recommended moving forward to the next dose level.

This is a historic moment; years of our lab's research on the Hippo-YAP signaling pathway are now being tested in patients. YAP101 is designed to unlock the heart's own repair mechanism, and we're thrilled to see it safely advancing through human trials.

Read The Texas Heart at Baylor College of Medicine press releast: The Texas Heart Institute at Baylor College of Medicine Leads First-in-Human Gene Therapy Trial to Regenerate Damaged Heart Tissue

Read the full press release: First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle